These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15883614)

  • 21. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).
    Oliveira EF; Santos-Martins D; Ribeiro AM; Brás NF; Cerqueira NS; Sousa SF; Ramos MJ; Fernandes PA
    Expert Opin Ther Pat; 2016 Nov; 26(11):1257-1272. PubMed ID: 27537201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
    Baldassarre D; Porta B; Camera M; Amato M; Arquati M; Brusoni B; Fiorentini C; Montorsi P; Romano S; Veglia F; Tremoli E; Cortellaro M;
    Nutr Metab Cardiovasc Dis; 2009 Sep; 19(7):481-90. PubMed ID: 19171469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One statin, two statins, three statins, more: similarities and differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Turkoski BB
    Orthop Nurs; 2011; 30(1):62-5; quiz 66-7. PubMed ID: 21278557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Schönbeck U; Libby P
    Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)].
    Igel M; Sudhop T; von Bergmann K
    Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
    Pfefferkorn JA
    Expert Opin Ther Pat; 2011 Feb; 21(2):187-203. PubMed ID: 21214503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum.
    Ridker PM
    Circulation; 2002 Jun; 105(22):2583-5. PubMed ID: 12045159
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipid lowering therapy in atherosclerosis.
    Aikawa M; Libby P
    Semin Vasc Med; 2004 Nov; 4(4):357-66. PubMed ID: 15861316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
    Piechota W; Piechota W
    Pol Merkur Lekarski; 2005 May; 18(107):511-5. PubMed ID: 16161944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation as a cardiovascular risk factor.
    Willerson JT; Ridker PM
    Circulation; 2004 Jun; 109(21 Suppl 1):II2-10. PubMed ID: 15173056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease.
    Poredos P; Jezovnik MK
    Curr Vasc Pharmacol; 2016; 14(6):534-546. PubMed ID: 27357185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary prevention trials performed with statins prior to the JUPITER trial].
    Baykan M
    Turk Kardiyol Dern Ars; 2009 Apr; 37 Suppl 4():14-7. PubMed ID: 19553757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins: the drugs for the 21st century?
    Ginter E; Simko V
    Bratisl Lek Listy; 2009; 110(10):664-8. PubMed ID: 20017462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of plaque echolucency in combination with inflammatory biomarkers on cardiovascular outcomes of coronary artery disease patients receiving optimal medical therapy.
    Ishizu T; Seo Y; Machino T; Kawamura R; Kimura T; Murakoshi N; Sato A; Takeyasu N; Watanabe S; Aonuma K
    Atherosclerosis; 2011 May; 216(1):120-4. PubMed ID: 21353222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers, C-reactive proteins and statins in acute coronary syndromes.
    Ray KK
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():31-3. PubMed ID: 18001319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.